A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Latest Information Update: 08 Mar 2026
At a glance
- Drugs Brenipatide (Primary)
- Indications Bipolar disorders; Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Acronyms RENEW-Bipolar-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Dec 2025 New trial record